Skip to main content
. 2015 Jul 1;8(7):8066–8074.

Figure 3.

Figure 3

Relationship between CDK5 expression and clinicopathological parameters. As is illustrated, NPC patients in T3 and T4 (91.8%, 45/49) expressed a noticeably higher level of CDK5 than those in T1 and T2 (53.2%, 33/62, P<0.001) (A). A considerably higher level of NPC expression regarding N category emerged among patients in N2 and N3 (79.5%, 66/83) than that in N0 and N1 (42.9%, 12/28, P=0.03) (B). Meantime, NPC patients in more advanced clinical stages demonstrated relatively stronger CDK5 expression (III and IV, 79.5%, 66/83, P<0.001) when compared with patients in early stages (I and II, 42.9%, 12/28) (C).